- Statistically Significant Improvement in Chorea Associated with Huntington s Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically.
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with.
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets
The U.S. Food and Drug Administration . | April 11, 2023
February FDA approvals include treatments for geographic atrophy, proteinuria, tardive dyskinesia and chorea associated with Huntington disease, and anemia.